United Therapeutics Corporation Announces Election of Jan Malcolm to its Board of Directors
27 Junho 2024 - 8:00AM
Business Wire
United Therapeutics Corporation (Nasdaq: UTHR), a public
benefit corporation, announced the addition of former Minnesota
Commissioner of Health Jan Malcolm to its Board of
Directors. Ms. Malcolm was elected by the company’s shareholders at
its annual meeting held on June 26, 2024.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240627817218/en/
Jan Malcolm was recently elected to
United Therapeutics' Board of Directors. (Photo: Business Wire)
Ms. Malcolm is an accomplished leader in health policy, public
health, and health care finance and delivery. She has demonstrated
a career-long dedication to improving the health of the public and
the care of complex populations. In recognition of her many
accomplishments, in February 2024 the American Medical Association
(AMA) presented Ms. Malcolm with the AMA Award for
Outstanding Government Service.
Ms. Malcolm was twice Minnesota’s Commissioner of Health under
three governors representing two political parties from 1999 to
2003 and from 2018 to 2023. During her tenure, Ms. Malcolm earned a
national reputation as one of the first health care leaders to
highlight health disparities and the impact of social determinants
of health. As Health Commissioner during the COVID-19 pandemic, she
also played an instrumental and visible role in educating the
public, creating dynamic and user-friendly systems for sharing
COVID-19 data with the people of Minnesota, and rapidly expanding
testing capacity. Ms. Malcolm also has significant healthcare
operational experience, having served as a vice president of the
Allina Health system, and as CEO of the Courage Center, a leading
provider of rehabilitation and health services for people with
disabilities.
Ms. Malcolm received a bachelor’s degree in philosophy and
psychology from Dartmouth College.
“We greatly value Ms. Malcolm’s deep healthcare operational
experience, as well as her leadership experience in public health
and government,” said Martine Rothblatt, Ph.D., Chairperson
and Chief Executive Officer of United Therapeutics. “We believe her
unique qualifications will support our efforts to revolutionize the
treatment of end-stage organ disease through the development,
commercialization, and distribution of manufactured organs.”
“It’s an honor to support United Therapeutics’ unique mission to
address critical unmet medical needs of patients,” said Ms.
Malcolm. “I look forward to working with the Board and senior
management, which collectively bring together the skills needed to
make a difference for patients with rare lung diseases and other
end-stage organ diseases.”
“I am proud to add Ms. Malcolm’s voice to our boardroom,” said
Christopher Causey, Chairman of the Nominating and
Governance Committee of the United Therapeutics Board of Directors.
“Her nomination is an important step in our efforts to refresh our
Board, which are focused on bringing in new skill sets to pursue
our patient-centric public benefit purpose and address the severe
shortage of transplantable organs.”
Ms. Malcolm filled the Board seat previously held by Professor
Katherine Klein, who did not stand for re-election at the company’s
2024 Annual Meeting of Shareholders.
“On behalf of the entire Board, I want to thank Professor Klein
for her decade of service,” said Christopher Patusky, Lead
Independent Director and Vice Chair of the United Therapeutics
Board of Directors. “During her tenure, she helped oversee a period
of exciting growth for our company as we laid the foundation for
our revolutionary organ manufacturing programs.”
United Therapeutics: Enabling Inspiration
At United Therapeutics, our vision and mission are one. We use
our enthusiasm, creativity, and persistence to innovate for the
unmet medical needs of our patients and to benefit our other
stakeholders. We are bold and unconventional. We have fun, we do
good. We are the first publicly-traded biotech or pharmaceutical
company to take the form of a public benefit corporation
(PBC). Our public benefit purpose is to provide a brighter
future for patients through (a) the development of novel
pharmaceutical therapies; and (b) technologies that expand the
availability of transplantable organs.
You can learn more about what it means to be a PBC here:
unither.com/pbc.
Forward-Looking Statements
Statements included in this press release that are not
historical in nature are “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, among others, our efforts to
innovate for the unmet medical needs of our patients, to benefit
our other stakeholders, and to pursue our public benefit purpose of
developing novel pharmaceutical therapies and technologies that
expand the availability of transplantable organs. These
forward-looking statements are subject to certain risks and
uncertainties, such as those described in our periodic reports
filed with the Securities and Exchange Commission, that could cause
actual results to differ materially from anticipated results.
Consequently, such forward-looking statements are qualified by the
cautionary statements, cautionary language, and risk factors set
forth in our periodic reports and documents filed with the
Securities and Exchange Commission, including our most recent
Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and
Current Reports on Form 8-K. We claim the protection of the safe
harbor contained in the Private Securities Litigation Reform Act of
1995 for forward-looking statements. We are providing this
information as of June 27, 2024, and assume no obligation to update
or revise the information contained in this press release whether
as a result of new information, future events or any other
reason.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240627817218/en/
Dewey Steadman at (202) 919-4097
https://ir.unither.com/contact-uthr/
United Therapeutics (NASDAQ:UTHR)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
United Therapeutics (NASDAQ:UTHR)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024